The Ministry of Food and Drug Safety in South Korea has granted regulatory approval for Vyzulta, according to a press release from Bausch Health.
The latanoprostene bunod ophthalmic solution 0.024% is indicated to reduce IOP in patients with open-angle glaucoma and ocular hypertension.
"Vyzulta is an important treatment option for people suffering from glaucoma, and we are committed to securing additional regulatory approvals for Vyzulta in countries around the world," Thomas J. Appio, president of Bausch + Lomb/International, said in the release.
Vyzulta is also approved in the United States,
Uncategorized